High-dose eicosapentaenoic acid and docosahexaenoic acid provided additional benefit to statins in preventing progression of fibrous coronary plaque in individuals adherent to therapy with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, a recent study found. 285 participants with stable coronary artery disease (CAD) on statins were randomized to omega-3 ethyl-ester or no omega-3 (control) for 30 months. Mean age of participants was 63.0 years; mean LDL-C ≤80 mg/dL. Researchers found:
- High dose eicosapentaenoic acid and docosahexaenoic acid (3.36 g daily) provided additional benefit to statins in preventing progression of fibrous coronary plaque over 30 months.
- Participants aged <64.2 years had significantly less progression of noncalcified plaque and fibrous, calcified, and total plaque volume compared with older participants.
- Eicosapentaenoic acid and docosahexaenoic acid prevented plaque progression in those on low‐intensity statin, but not high‐intensity statin.
Alfaddagh A, Elajami TK, Ashfaque H, Saleh M, Bistrian BR, Welty FK. Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: A randomized clinical trial. [Published online ahead of print December 15, 2017]. J Am Heart Assoc. doi:10.1161/JAHA.117.006981.
This Week's Must Reads
Detection & Management of Resistant Hypertension, Hypertension; ePub 2018 Sep 13; Carey, et al
Does Aspirin Prevent CV Events in Older Adults?, N Engl J Med; ePub 2018 Sep 16; McNeil, et al
Timing of ICD Placement From Last Hospitalization for HF, Circulation; ePub 2018 Sep 13; Ambrosy, et al
FFR and Quality of Life After PCI, Circulation; ePub 2018 Sep 18; Nishi, et al
VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251
Must Reads in Hypercholesterolemia
Racial Differences in Statin Use, JAMA Cardiol; ePub 2018 Jun 13; Nanna, et al
LLT Use in Patients with Elevated LDL-C, Circ Cardiovasc Qual Outcomes; ePub 2018 May 10; Virani, et al
Evolocumab in Differing Patient Populations , J Pharmacokinet Pharmacodyn; ePub 2018 May 7; Kuchimanchi, et al
LDL-C Targets in Elderly Statin Users After ACS, J Am Heart Assoc; ePub 2018 May 12; Alter, et al
Patient Perspectives on Statin Therapy, Clin Cardiol; ePub 2018 May 10; Brinton